Global Mycoplasma Testing Market is set to witness a healthy CAGR of 11% by 2027 - Thermo Fisher Scientific; Charles River Laboratories; Merck KGaA; Lonza; PromoCell GmbH

Mycoplasmas are the smallest known free-living microorganisms and are frequent contaminants of mammalian cell cultures. For the safety and purity of vaccines and other biological cell-derived products, it is very important that the cell substrates and unprocessed bulk materials are free of adventitious agents, including mycoplasma. In many instances, mycoplasmas vary from other forms of bacteria, thus making them difficult to culture and identify. Testing is done to detect mycoplasma like Mycoplasma hominis, Mycoplasma genitalium, Mycoplasma pneumoniae, and Ureaplasma urealyticum which can cause nongonococcal urethritis (NGU), prostate inflammation (prostatitis), vaginal discharge, and pelvic inflammatory disease (PID) in both men and women.

Growing Concerns of Cell Culture Contamination to Trigger the Demand of Mycoplasma Testing Market

Mycoplasmas frequently contaminate the fluids used in bioprocessing and cell culture. It is often known that primary cell cultures have a minimum contamination rate of 1% and continuous cell cultures have a contamination rate of between 15% and 35% due to mycoplasma. Inefficient culturing techniques or malfunctioning laboratory apparatus can both result in mycoplasma contamination.

Reusing pipet tips is an example of poor culture technique which might spread the contaminant by transferring mycoplasma-infected media into otherwise sterile media. Further, a faulty laminar flow might spread mycoplasma-carrying dust and aerosols throughout a biosafety cabinet, contaminating all the medium and cells within.

The mycoplasmas enter the cell culture through many difficulties to trace sources. These include healthcare workers in the lab, serum, materials used in cell culture, water baths, incubators, etc. Among the aforementioned sources, contamination by humans' accounts for the highest share. The contaminants can be transmitted through dirty clothing, lab gear, human speaking close to a laminar airflow, the scalp, sneezing, coughing, etc. Also, wherever the cell cultures are kept, a steady inflow of people will raise the possibility of contamination. Out of over 190 total species of mycoplasma, only 20 distinct mycoplasma species of human, bovine, and porcine origin have been found in cell culture. Eight of the species account for almost 95% of all mycoplasma contamination in cell culture. These include M. arginini (bovine), M. fermentans (human), M. hominis (human), M. hyorhinis (porcine), M. orale (human), M. pirum (human), M. salivarium (human), and Acholeplasma laidlawii (bovine).

Routine testing is the best protection against mycoplasma contamination which can identify contaminated cultures and reagents. In the case of batch adulteration or a product recall, contamination of cell substrates used in the development of biopharmaceuticals constitutes a serious economic risk for manufacturers as well as a safety concern for patients. Regular mycoplasma testing is needed to be performed during the product manufacturing and development phase to reduce these risks.

Aggressive Growth Strategies Adopted by the Market Players and Laboratories in Mycoplasma Testing Market

Constant innovations and developments in mycoplasma detection have enabled all the market players to develop an innovative, rapid and easy-to-use tests. Such innovations tend to offer a competitive edge to all manufacturers and hence, all the leading companies are focusing on increasing their investments for new product development and expanding their reach to strengthen their current position in the mycoplasma testing market.

Some of the recent developments are listed below-
• In February 2023, SwiftDx announced the launch of its mycoplasma detection kit. The SwiftDx Mycoplasma Detection Kit is a new lateral flow test for the detection of mycoplasma contamination thus providing a faster and convenient solution.
• In April 2022, AlphaBiolabs launched sexually-transmitted infection (STI) testing to detect chlamydia, gonorrhoea, mycoplasma genitalium, mycoplasma hominis, trichomoniasis, ureaplasma parvum (UTI), and ureaplasma urealyticum (UTI).

Competitive Landscape Analysis: Mycoplasma Testing Market

The global mycoplasma testing market is marked by the presence of established and emerging market players such as Thermo Fisher Scientific, Inc. (US); Charles River Laboratories International, Inc. (US); Merck KGaA (Germany); Lonza Group (Switzerland); PromoCell GmbH (Germany); American Type Culture Collection (US).

Irrespective of the arising challenges in mycoplasma testing market such as long turnaround time, quality control concerns, long analytical and lead time, etc. The global mycoplasma testing market has a huge potential to grow at a decent rate and is expected to gain a smooth momentum in the upcoming years due to a primary focus on technological innovations, wider adoption by biopharmaceutical manufacturers across the world, and development of rapid mycoplasma testing by key market players operating in mycoplasma testing market.

Get Detailed Insights on Mycoplasma Testing Market with a Sample PDF Copy @ https://meditechinsights.com/mycoplasma-testing-market/

Ruta Halde
Associate, Medi-Tech Insights
121/7E Avenue Franklin Roosevelt,
1050 Brussels, Belgium
+32 498 86 80 79
info@meditechinsights.com
https://meditechinsights.com/

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

This release was published on openPR.